|1.||Pagnotta, A: 1 article (01/2000)|
|2.||Specchia, N: 1 article (01/2000)|
|3.||Toesca, A: 1 article (01/2000)|
04/01/1993 - "In this study we report the presence of cytosolic Type II EBS in a series of 10 normal ovaries, 42 primary ovarian tumors, and 14 metastatic deposits. "
09/01/1994 - "All these tumors specifically expressed type II EBS, while only 3 of 8 cases contained low amounts of ER. "
05/28/1993 - "The flavonoid-induced enhancement of type-II EBS levels is accompanied by increased sensitivity of cancer cells to the inhibitory effect of low Q concentrations. "
04/01/1993 - "No correlation was found between Type II EBS levels and the common clinicopathological characteristics of the tumors. "
07/01/1990 - "Although the precise functional role of type II EBS is still unknown, their presence may reflect an hormonal sensitivity of these tumors."
|2.||Colorectal Neoplasms (Colorectal Cancer)
|3.||Ovarian Neoplasms (Ovarian Cancer)
09/04/1995 - "The ability of TAM to interact only with cytosolic Type II EBS seems also to be a characteristic of ovarian cancer tissue and to be shared by several TAM metabolites. "
12/01/1990 - "Our results suggest that Q may regulate ovarian cancer cell growth through a mechanism involving a binding interaction with type II EBS. "
09/01/1995 - "This study was carried out to determine the effect of 15 different natural and synthetic chalcones on the proliferation of both established and primary ovarian cancer cells expressing type II oestrogen binding sites (type II EBS). "
04/01/1993 - "The presence of Type II EBS in ovarian cancer could be of clinical importance since it has been demonstrated that bioflavonoids, through the interaction with Type II EBS, may exert a growth inhibitory activity both alone or in combination with chemotherapeutic agents on ovarian cancer cell lines and primary tumors."
09/04/1995 - "The aim of this study was to investigate the interaction of tamoxifen (TAM) with the so-called Type II estrogen binding sites (Type II EBS) in both the cytosolic and the nuclear fraction of the ER-negative A 2780 human ovarian cancer cell line and in an ER-negative ovarian cancer tissue. "
|4.||Breast Neoplasms (Breast Cancer)
02/01/1987 - "Using a saturation analysis over a wide range of [3H]estradiol at two temperatures 4 and 22 degrees C we have determined unoccupied (4 degrees C) and total (22 degrees C) type II estrogen binding site (EBS) levels in individual cytosols of 100 patients with breast cancer (50 post and 50 premenopausal). "
01/01/1991 - "We looked for the presence of type II EBS and the effect of Q on the proliferation of an Adriamycin-resistant estrogen-receptor-negative human breast-cancer cell line (MCF-7 ADRr). "
11/01/1982 - "We also present a series of 25 individual human breast cancer specimens which were analyzed for cytoplasmic ER and progesterone receptor by sucrose density gradient centrifugation and for nuclear ER and type II EBS by the sucrose pad assay. "
05/28/1993 - "We show that flavonoids positively regulate type-II estrogen-binding site (type-II EBS) levels both in MCF-7 (ER-positive) and in MDA-MB231 (ER-negative) breast-cancer cells. "
11/01/1982 - "Two antiestrogens, tamoxifen and nafoxidine, were also tested for their ability to bind to ER and type II EBS in human breast tumors. "
|6.||type II estrogen binding site